Abstract p38a mitogen-activated protein kinase (MAPK) is activated in cancer cells in response to environmental factors, oncogenic stress, radiation, and chemotherapy. p38a MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), and regulates the production of cytokines in the tumor microenvironment, such as TNF-a, interleukin-1b (IL-1b), . p38a MAPK is highly expressed in human cancers and may play a role in tumor growth, invasion, metastasis, and drug resistance. LY2228820 dimesylate (hereafter LY2228820), a trisubstituted imidazole derivative, is a potent and selective, ATP-competitive inhibitor of the a-and b-isoforms of p38 MAPK in vitro (IC 50 ¼ 5.3 and 3.2 nmol/L, respectively). In cellbased assays, LY2228820 potently and selectively inhibited phosphorylation of MK2 (Thr334) in anisomycinstimulated HeLa cells (at 9.8 nmol/L by Western blot analysis) and anisomycin-induced mouse RAW264.7 macrophages (IC 50 ¼ 35.3 nmol/L) with no changes in phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc 10 mmol/L. LY2228820 also reduced TNF-a secretion by lipopolysaccharide/IFNg-stimulated macrophages (IC 50 ¼ 6.3 nmol/L). In mice transplanted with B16-F10 melanoma, tumor phospho-MK2 (p-MK2) was inhibited by LY2228820 in a dose-dependent manner [threshold effective dose (TED) 70 ¼ 11.2 mg/kg]. Significant target inhibition (>40% reduction in p-MK2) was maintained for 4 to 8 hours following a single 10 mg/kg oral dose. LY2228820 produced significant tumor growth delay in multiple in vivo cancer models (melanoma, non-small cell lung cancer, ovarian, glioma, myeloma, breast). In summary, LY2228820 is a p38 MAPK inhibitor, which has been optimized for potency, selectivity, drug-like properties (such as oral bioavailability), and efficacy in animal models of human cancer. Mol Cancer Ther; 13(2); 1-11. Ó2013 AACR.
Introduction p38a mitogen-activated protein kinase (MAPK; a, b, d, and g isoforms) is a member of the MAPK family, which also includes JNK and ERK (1) . The a-isoform of p38, known as p38a MAPK or MAPK14, is activated in response to environmental factors such as lipopolysaccharide (LPS), cytokines, heat/osmotic shock, radiation, and chemotherapy (2) . Activation is accomplished by phosphorylation of the Thr180 and Tyr182 residues by upstream MAPK kinases, including MKK3 and MKK6 (3) . p38a MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), which then phosphorylates tristetraprolin, regulating the posttranslational processing of various proteins (4) .
p38 MAPK plays a key regulatory role in the production of cytokines such as TNF-a, interleukin-1b (IL-1b), IL-6, and IL-8 (CXCL8; refs. [4] [5] [6] . Given the critical role of p38a MAPK in regulating these cytokines, there is keen interest in identifying p38 MAPK inhibitors for use in inflammatory diseases such as rheumatoid arthritis, Crohn disease, and the pain associated with inflammation (7, 8) . The role of inflammation in cancer initiation and progression has been widely studied. Soluble factors produced by the tumor and by the tumor microenvironment (TME) can activate p38 MAPK and promote tumorigenesis, angiogenesis, invasion, metastasis, and resistance to anticancer agents (2, 6, 9, 10) . For example, tumor-infiltrating macrophages, which possess abundant amounts of activated p38a MAPK, are associated with adverse prognosis in cancer (11, 12) . We have previously shown that pharmacologic inhibition of p38 MAPK activity in tumor-infiltrating macrophages in vivo is associated with an antitumor effect (13) . Similarly, IL-6 and CXCL8 have proliferative and proangiogenic properties; importantly, elevated levels of these cytokines are correlated with poor prognosis in breast and ovarian cancers (14, 15) .
The actions of p38 MAPK in cancer involve aberrant interactions between the tumor and its microenvironment, and these interactions may differ among tumor types. There are data that support both direct (tumormediated) and indirect (via TME) modes of action for p38 MAPK in oncogenesis with a complex interplay between the two likely important for disease progression. For example, both melanoma cells and the associated tumor-infiltrating leukocytes secrete abundant amounts of cytokines (such as IL-1, IL-6, CXCL8, and Gro-a), which are known to promote angiogenesis, growth, invasion, and metastasis (16) (17) (18) (19) (20) . Ovarian cancer cells produce TNF-a and CXCL8 upon p38a MAPK activation, and these cytokines may act in an autocrine manner to promote peritoneal colonization and tumor vascularization (21) . The U-87MG glioma, A-2780 and SK-OV-3 ovarian cancers, and PC3 prostate cancer all secrete VEGF, basic fibroblast growth factor (bFGF), EGF, and IL-6; and importantly, secretion of these cytokines can be significantly reduced by p38 MAPK inhibition (6, 22) . Furthermore, pretreatment of tumor cells with LY2228820 or p38a MAPK short hairpin RNA (shRNA) reduces cord formation in a tumor/adipocyte-derived stem/endothelial colony-forming cell coculture system, supporting a p38 MAPK-mediated effect of the tumor on the TME (6) .
p38 MAPK activity also influences TME biology, an often overlooked aspect of cancer therapy, but one that likely plays a profound role in tumor-host dynamics. In multiple myeloma, p38 MAPK inhibitors downregulate IL-6 secretion by bone marrow stromal cells (BMSC), inhibit myeloma cell proliferation (23) (24) (25) (26) , and reduce osteoclastic bone destruction (24, 27) . Inhibition of p38 MAPK also reduces production of VEGF and plateletderived growth factor by BMSCs in vitro (28) . In response to neutrophil elastase, lung cancer cells produce CXCL8, which stimulates the growth of lung cancer cells in vitro (29) (30) (31) in a p38a MAPK-dependent manner, indicating that neutrophils in the TME may activate the p38 MAPK signaling pathway in tumor cells to promote lung cancer growth (32) . Furthermore, secretion of CXCL8 by both the tumor and TME increases proliferation of ovarian cancer cells in vitro and in vivo (30, 32) . IL-6, secreted from adipose stromal cells to promote migration and invasion of breast cancer cells (33) , likely requires p38 MAPK because its direct substrate, MK2, contributes to IL-6 mRNA stabilization (34) . Finally, from the perspective of immune surveillance, activation of p38 MAPK is associated with enhanced dendritic cell tolerance during melanoma progression (35) . Conversely, p38 MAPK inhibition restores the function of monocyte-derived dendritic cells in myeloma, limiting evasion of the tumor from immune surveillance (36) .
Given the substantial body of evidence supporting a role for p38 MAPK in cancer progression, we developed a potent and selective p38 MAPK inhibitor, LY22288220 dimesylate (hereafter LY2228820), and characterized its activity using in vitro biochemical and cellular systems and in vivo xenograft models in which tumor and/or TME p38 MAPK activity has been implicated. These results demonstrate that LY2228820, a novel p38 MAPK inhibitor, provides an opportunity for the treatment of cancer through modulation of aberrant interactions between the tumor and its supportive microenvironment, a therapeutic strategy that merits further clinical evaluation.
Materials and Methods

Crystallography
For crystallographic studies, human p38 was expressed in Escherichia coli and purified by affinity and gel filtration chromatography. Purified protein was in a solution containing 150 mmol/L NaCl, 20 mmol/L Hepes pH 7.5, 10 mmol/L methionine, 5 mmol/L dithiothreitol, and 10% glycerol. Protein at 16.2 mg/mL was mixed in 1% bOG and 1.25 mmol/L LY2228820 before crystallization drops were set up. Diffraction-quality crystals of p38/LY2228820 were grown by the vapor diffusion technique at 21 C under the reservoir condition 0.1 M Na cacodylate, pH 6.2, 10% PEG 3350. Crystals belong to space group P2 1 2 1 2 1 with unit cell parameters a ¼ 66.558 Å , b ¼ 74.456 Å , c ¼ 78.691 Å . The diffraction data (resolution of 1.97 Å ) were collected on beam line ID-31 (then SGX-CAT) at the advanced photon source (APS; Argonne National Laboratories). The crystal structure was determined by the method of molecular replacement and was refined using a maximum likelihood target as incorporated in the program CNX2000 first and then using Refmac5 (R work ¼ 0.2303, R free ¼ 0.2666).
Kinase assays
For p38-MAPK enzymatic assays (enzyme sourced from either Millipore or Roche), 33 P-ATP radiometric filter binding (Millipore MAPH plates) was used with an EGFR peptide substrate, KRELVEPLTPSGEAPNQALLR (Multiple Peptide Systems), and 100 mmol/L (p38a) or 20 mmol/L (p38b, p38g) ATP run under linear velocity conditions. LY2228820 was also tested against a panel of enzymatic kinase assays (internal assays and Merck Millipore KinaseProfiler; ref. 37 ; all human sequence) to assess the relative kinase selectivity in vitro. The initial screen was conducted at 20 mmol/L followed by 10-point concentration-response curves (1:3 serial dilutions from 20 mmol/L to 1 nmol/L). All assays were either 96-well radiometric filter binding ( 33 P-ATP phospho-cellulose or glass fiber) or fluorescence polarization formats under linear velocity conditions, at or below the Km[ATP] (typically 30-120 minutes resulting in 10% ATP conversion) using 1% to 4% dimethyl sulfoxide (DMSO) final (depending on enzyme tolerance for solvent). IC 50 values were calculated using 4-parameter nonlinear regression (ActivityBase software, IDBS).
Cell lines
All LPS/IFN-g-stimulated TNF-a release by mouse peritoneal macrophages in vitro Mouse peritoneal macrophages were activated in vivo by 3% thioglycollate injection (intraperitoneal, administered 4 days before harvest), then harvested and plated in 96-well microtiter plates. The cells were treated with LY2228820 (range of 20 mmol/L to 1 nmol/L, 10 1:3 serial dilutions) for 0.5 hours, and then incubated with LPS/ IFN-g for 2 hours (to stimulate p38-MAPK) and the media measured for TNF-a by ELISA (R&D Systems). 
Anisomycin-stimulated HeLa cell kinase selectivity assay (Western blot analysis)
HeLa cells were pretreated with LY2228820 for 1 hour before stimulation with anisomycin (10 mg/mL) for 45 minutes. Cells were then lysed in a protein lysis buffer [containing protease (leupeptin 10 mg/ml, trypsin-chymotrypsin inhibitor 10 mg/ml, N-p-Tosyl-L-phenylalanine chloromethyl ketone 10 mg/mL, aprotinin 10 mg/mL, Nap-Tosyl-L-arginine methyl ester hydrochloride 2 mmol/L, benzamidine hydrochloride hydrate 5 mmol/L) and phosphatase inhibitors (sodium metavanadate anhydrous 1 mmol/L, p-nitrophenyl phosphate 15 mmol/L, microcystin 1 mmol/L), okadaic acid 1 mmol/L; SigmaAldrich] and proteins were analyzed by Western blotting for p38, JNK, and p44/42 (ERK1/2) pathway activities. All antibodies were obtained from Cell Signaling Technologies: phospho-MK-2 (Thr334), phospho-p38 MAP kinase (Thr180/Tyr182), total p38a MAPK antibody, phospho-ATF2 (Thr71), phospho-JNK (Thr183/Tyr185), phosphocJun (Ser63), phospho-p44/42 MAPK (Thr202/Tyr204), and phospho-cMyc (Thr58/ser62).
Phosphorylation of MK2 in mouse B16-F10 melanoma tumors
In vivo target inhibition. Murine B16-F10 melanoma cells were cultured in Dulbecco's Modified Eagle Medium supplemented with L-glutamine, high glucose and 10% FBS (GIBCO 11965-092). C57/bl6 mice (Charles River) were implanted in the rear flank with B16-F10 cells (2 Â 10 6 ), and when tumors reached approximately 200 mm 3 in size, were dosed orally with LY2228820 in 1% carboxymethylcellulose/0.25% Tween 80. Two hours postdose, tumors were excised, homogenized, and lysed for Western blot analysis. MK2 phosphorylation (pThr334), normalized to total glyceraldehyde-3-phosphate dehydrogenase, was quantified by chemiluminescent detection. The 50% or 70% threshold effective dose (TED 50 and TED 70 , respectively) was calculated (JMP software, SAS) to approximate effective dose ranges for testing of LY2228820 in xenograft models, that is, where significant target inhibition was observed. The TED 50 or TED 70 is defined as the dose where a statistically significant effect was achieved, and there was at least 50% or 70% inhibition, respectively, compared with vehicle control.
In vivo pharmacodynamics. Mice bearing B16-F10 tumors were given a single dose of LY2228820 approximating the TED 70 (10 mg/kg p.o.) and sampled for compound exposure and tumor phospho-MK2 (p-MK2) over various time points.
In vivo phosphorylation of MK2 in mouse and human peripheral blood mononuclear cells See Supplementary Methods ( Supplementary Fig. S1 ). Fig. S2 ).
In vivo tumor models All studies were done in accordance with AALACaccredited institutional guidelines. Female immunocompromised mice received food and water ad libitum and were acclimated for at least 1 week before xenograft implantation. Cells used in xenograft studies were pathogen tested and authenticated by STR analysis. Banked master stocks were returned to within approximately 6 months, or if inconsistencies in growth behavior were observed. Cells originated from the ATCC unless otherwise indicated.
Subcutaneous cell-based inoculations were performed in a 1:1 volume (200 mL total) with Matrigel (BD Biosciences) and were injected in the right rear flank. Inoculums and host animals were as follows: 5 Â 10 6 cells for U-87MG, SK-OV-3x-luc#1 (M. Harrington and S. Brutkiewicz, Indiana University, Indianapolis, IN), 786-O, and 1 Â 10 7 cells for A549 were implanted into athymic nude mice (Harlan); 2 Â 10 6 for A-2780 (NCI DCTD) into CD1 nu/nu mice (Charles River); and 5 Â 10 6 for OPM-2 (DSMZ GmBH) into CB-17 SCID mice (Taconic) irradiated with 2.5 Gy within 24 hours of implant. MDA-MB-468 breast cancer xenografts were initiated as implants of established cell-derived tumors in athymic nude mice at Oncotest GmBH. Tumors were allowed to establish for at least 1 week before randomization into treatment groups; treatments began with tumors of 50 to 250 mm 3 . LY2228820 was prepared in 1% CMC/0.25% Tween 80 or HEC 1%/Tween 80 0.25%/AF 0.05% and delivered by oral gavage (10 mL/kg, v/v). Comparable vehicle control groups were run in parallel. Dosages, dosing schedules, and cohort sizes are described in the legend for each study. Tumor size and body weight were recorded 1 to 2 times per week. Tumor size was determined by caliper and tumor volume (mm 3 ) was estimated using the formula: l Â w 2 Â 0.536, where l is the larger and w is the smaller of the perpendicular diameters. Tumor data were analyzed by repeated measures using ANOVA with a Tukey post hoc test.
SK-OV-3 and 786-O orthotopic xenograft models
Female athymic nude mice (20-25 g; Harlan) received intraperitoneal injections (2 Â 10 6 cells in 0.2 mL PBS) of SK-OV-3 luciferase-labeled tumor cells or luciferase- Figure 1 . A, depiction of SAR progression from initial actives (1) to candidate molecule, LY2228820 (2). The candidate compound 2 was identified from iterative SAR on hits found in the Lilly compound collection, as represented by the generic structure 1. Molecules were designed to optimize binding to the ATP pocket of p38a MAPK, reduce the potential of off-target cross-reactivity, and minimize CYP P450 activity. B, crystal structure of LY2228820 in the ATP-binding site of p38a MAPK. The amino azabenzimidazole moiety in LY2228820 forms 2 hydrogen bonds with the hinge backbone. The fluoro-phenyl group projected from the center imidazole is buried in a hydrophobic pocket near the gate-keeper residue Thr
106
, which has close van der waals contact between its side chain and the phenyl ring. The fluoro group has B€ urgi-Dunitz interaction with 2 backbone carbonyls and also has close interaction with the side chain of Leu
104
. Compared with the binding conformation of inhibitors like SB203580, LY2228820 has a more extended warhead group and hence shifted hinge position. Although the fluoro-phenyl group is similarly bound, the lower position of the P-loop in the LY2228820 structure creates a smaller cavity (closer distance) between the Nterminal lobe and the C-terminal lobe.
labeled 786-O cells (2 Â 10 6 in 0.025 mL PBS) implanted into the renal capsule of the surgically accessed left kidney. On days 10 and 21 respectively, animals with a signal demonstrating tumor presence were randomized into study groups and started on drug treatments. Anesthetized animals were imaged weekly with an IVIS Spectrum (Caliper Life Sciences) following intraperitoneal injection 150 mL of 15 mg/mL of D-luciferin (Sigma-Aldrich). Data review and analysis were performed with the Living Image 3.0 program. Tumor growth was measured for each animal as luminescent light intensity or Total Flux (P/S) with fixed region of interest data from the IVIS Spectrum. Statistical comparisons used Dunnett's ANOVA and t test measures between the treatment groups.
Mouse B16-F10 melanoma lung metastasis model B16-F10 melanoma cells (50,000) were injected into the tail vein of nude mice 1 day before treatment. Mice were orally dosed by gavage with vehicle or LY2228820 (either 10 or 30 mg/kg) 3 times a day, on a schedule of 4 days on/3 days off for 14 consecutive days (n ¼ 10 animals/group). Lung tissues were collected and placed in 10% neutralbuffered formalin followed by 70% ethanol storage. Individual lung metastases were counted visually. Data were analyzed by ANOVA.
Results
Utilizing molecular modeling to guide medicinal chemistry efforts, a series of molecules were designed from early screening actives to optimize binding to the ATP pocket of p38a MAPK, reduce potential off-target kinase activity, achieve drug-like properties, and minimize the risk of drug-drug interactions. The candidate compound 2 was identified from iterative SAR on hits found in the Lilly compound collection, as represented by the generic structure 1 (Fig. 1A) . Awareness of potential CYP activity associated with the imidazole central core led to the difluoroaryl substitution at C-2 with other sterically bulky groups such as tert-butyl as found in the candidate (38) . The contribution of the 4-fluorophenyl group to enzymatic affinity can be understood by recognizing that it occupies a hydrophobic pocket of the ATP binding site near the gatekeeper Thr106, as seen in the x-ray co-crystal structure (Fig. 1B) . In addition, modifications of the benzimidazole substituent at C-5 and the aromatic group, R2, at C-4 of the imidazole were made in consideration of improving cell-based potency as well as pharmacokinetic properties.
In vitro characterization data
One compound from the benzimidazole SAR, LY2228820 (Fig. 1) , was found to be a very potent, ATPcompetitive inhibitor of both the a and b isoforms of p38 MAPK in vitro (IC 50 ¼ 5.3 and 3.2 nmol/L, respectively) with >1,000-fold selectivity for p38a MAPK versus 178 other kinases tested (Table 1 and Supplementary Table  S1 ). Within the MAPK family, LY2228820 was >1,000-fold more selective for p38a versus p38d, p38g, ERK1, and ERK2; >50-fold more selective for p38a versus JNK1; 30-fold more selective for p38a versus JNK3; and 15-fold ; by surface plasmon resonance; data not shown). LY2228820 was also tested in a wide array of assays to assess any off-target effects on nonkinase enzymes, ion channels, transporters, G-protein-coupled receptors, nuclear hormone receptors, and others; and importantly, no significant off-target effects were observed (Cerep Profiling Service; data not shown).
To confirm p38a MAPK-dependent biologic activity, LY2228820 was tested in a series of cell-based assays (Table  1 and Fig. 2 ). LY2228820 potently inhibited phosphorylation of the p38a MAPK substrate, MK2 (Thr LY2228820 was screened for cytotoxicity across >50 cancer cell lines using both standard monolayer and soft agar culture conditions. Despite evidence of p38 MAPK inhibition and consequent changes in cellular cytokines cited above, single agent antiproliferative effects were not observed across the cell lines and EC 50 values were greater than 2 mmol/L in all cases (data not shown).
In vivo tumor target inhibition
LY2228820 was orally bioavailable in the mouse, with a T 1/2 ¼ 2.8 hours (single oral dose of 20 mg/kg). In mice implanted with B16-F10 melanoma, tumor phospho-MK2 was effectively inhibited by LY2228820 in a dose-dependent manner (TED 50 ¼ 1.95 mg/kg, TED 70 ¼ 11.17 mg/kg; Fig. 3A ). Significant target inhibition (>40% inhibition of phospho-MK2) was maintained for approximately 4 to 8 hours following a single 10 mg/kg oral dose (Fig. 3B) . Figure 4 . Effect of LY2228820 in solid tumor xenograft models in vivo. A549 NSCLC xenograft: nude mice were treated orally with vehicle (open symbols) or LY2228820 (closed symbols) at 20 mg/kg 3 times a day from days 4 to 13. Starting day 14, one LY2228820-treated group continued with the daily dosing regimen (* "Daily") whereas a second group switched to an intermittent 3 days on/3 days off drug treatment schedule (~"Intermittent"). Comparable vehicle control groups (*,~) were run in parallel; n ¼ 10 animals/group. A significant decrease in tumor volume occurred with both continuous and intermittent dosing strategies; efficacy of LY2228820 was not significantly different on the 2 schedules. A2780 ovarian xenograft: nude mice bearing xenografts began treatment 15 days after implantation. Vehicle (*) or LY2228820 (*) 10 mg/kg was given orally, 3 times a day, on a schedule of 4 days on/3 days off for 3 weeks; n ¼ 10 animals per group. Significant tumor growth inhibition occurred throughout the treatment phase. U-87MG glioma xenograft model: nude mice were treated orally with vehicle (*) or LY2228820 (*) twice a day at 14.7 mg/kg continuously on days 11 to 28; n ¼ 10 animals/group. (Continued on the following page.)
In vivo pharmacodynamic biomarker
To understand whether peripheral blood mononuclear cell (PBMC) could be used as a potential surrogate biomarker for p38 MAPK inhibition, PBMCs were collected from mice dosed orally with LY2228820 or from patients with multiple myeloma (treated with LY2228820 ex vivo). With either mouse or human PBMC, LY2228820 inhibited MK2 phosphorylation: mouse in vivo TED 50 ¼ 1.01 mg/kg (compound exposure approximately 100 nmol/L) and human ex vivo IC 50 ¼ 0.12 mmol/L ( Supplementary Fig.  S1A and S1B).
In vivo efficacy
Based on pharmacokinetic and pharmacodynamic data, subsequent in vivo subcutaneous xenograft studies were conducted at doses that were predicted to yield >50% target inhibition (ranging from 10 to 30 mg/kg p.o., either twice a day or 3 times a day). LY2228820 up to 30 mg/kg 3 times a day was well tolerated in all studies and no significant weight loss (<10%) or animal death attributable to drug treatment was observed.
LY2228820-treated A549 NSCLC xenografts demonstrated significant tumor growth inhibition under 2 different dosing schedules. LY2228820 (20 mg/kg 3 times a day) was administered for 34 days on a continuous daily schedule (days 4-38) or an intermittent schedule (3 day on, then 3 day off) starting on day 16. Both the continuous and intermittent treatment schedules resulted in significant tumor growth delay after 3 weeks of treatment compared with the vehicle control (P < 0.05, days 27-38). Tumor growth was not significantly different on the 2 LY2228820 treatment schedules. A number of other solid tumor xenograft models demonstrated highly significant tumor growth inhibition when LY2228820 was administered orally twice a day or 3 times a day in a range from 10 to 30 mg/kg. A complete attenuation of tumor growth occurred in the U-87MG glioma model during the treatment period (days 11-28, P < 0.001); the A-2780 ovarian, MDA-MB-468 breast and OPM-2 myeloma xenografts were inhibited 72% (P < 0.01), 60% (P < 0.001), and 42% (P < 0.05), respectively, on the last day of study treatment (Fig. 4) . Importantly, shRNA knockdown of p38a MAPK led to significant U-87MG tumor growth delay, further substantiating a role for p38 MAPK in tumorigenesis ( Supplementary Fig. S2 ). In addition, LY2228820 dosed intermittently at 10 and 30 mg/kg reduced the number of lung metastases in the B16-F10 syngeneic mouse melanoma model; metastases were significantly reduced by 57% at 30 mg/kg (P ¼ 0.012; Fig. 4 ).
Several other cell-based and patient-derived subcutaneous xenograft models did not demonstrate tumor growth inhibition with LY2228820 treatment. The effect of LY2228820 was compared in two of these xenograft models with both flank and orthotopic implantation. Luciferase-expressing SK-OV-3 ovarian cell xenografts implanted into the peritoneal cavity were highly responsive to LY2228820, demonstrating not only 50% to 51% tumor growth inhibition with both 10 and 30 mg/kg 3 times a day intermittent dosing (measured by area under the curve for bioluminescence; P < 0.05; Fig.  5 ) but also lower total excised tumor weight and reduced ascites in a separate study with 10 mg/kg on a daily schedule. Subcutaneously implanted SK-OV-3 xenografts were unresponsive to LY2228820 on the same schedules (Fig. 5) . Similarly, LY2228820-induced tumor growth inhibition was not observed in the subcutaneously implanted 786-O renal carcinoma xenograft employing a daily 30 mg/kg 3 times a day schedule (Fig. 5) . However, luciferase-labeled 786-O cell xenografts orthotopically implanted into the renal capsule of the left kidney demonstrated a 44% decrease in luminescence after 3 weeks (P < 0.05), and 35% reduced average excised tumor weight (P < 0.05) when treated on the same schedule with the same dose (Fig. 5) .
Discussion
Following an extensive medicinal chemistry effort to identify potent, selective, and orally active inhibitors of p38 MAPK (38, 39) , a series of trisubstituted imidazole derivatives were synthesized and tested. This effort resulted in the synthesis of LY2228820 and, for the first time, characterization of its crystal structure in complex with p38a MAPK. LY2228820 is a potent and selective ATP-competitive inhibitor of the a and b isoforms of p38 MAPK in vitro. In cell-based assays, LY2228820 potently and selectively inhibited p38a MAPK substrate phosphorylation (p-Thr334-MK2) with no effects on phosphorylation of p38a MAPK, JNK, ERK1/2, c-jun, ATF2, or cMyc. Consistent with established p38a MAPK signaling activity, LY2228820 also potently reduced LPSstimulated cytokine secretion by both macrophages and A549 NSCLC cells.
LY2228820 did not demonstrate direct antiproliferative activity in the tumor cell lines tested in vitro despite clear repression of downstream signaling (Fig. 2 and data not shown) but did demonstrate antitumor activity in vivo. In tumor models, a tight pharmacokinetic/ (Continued.) Significant tumor growth inhibition was observed on days 21 to 35. OPM-2 myeloma xenograft: nude mice were treated orally with vehicle (*) or LY2228820 (*) twice a day at 30 mg/kg continuously; n ¼ 10 and 9 animals/group for vehicle and LY2228820, respectively. Significant tumor growth inhibition was observed with LY2228820 after 10 days of treatment and throughout the remainder of the study. MDA-MB-468 xenograft: subcutaneous MDA-MB-468 breast cancer xenografts were implanted into nude mice. Vehicle (*) or LY2228820 (*) was administered orally, 30 mg/kg twice a day (n ¼ 7 per group). LY2228820 treatment resulted in significant tumor growth inhibition. B16-F10 melanoma syngeneic mouse model: cells were injected into the tail vein of nude mice 1 day before compound treatment. Vehicle or LY2228820 was administered orally at 10 or 30 mg/kg on a 4 days on/3 days off schedule for 14 days (n ¼ 10 animals per group). All animals were examined for lung metastases at the end of study. A significant reduction in lung mets was observed following treatment with 30 mg/kg LY2228820. Statistics: Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001 by ANOVA.
pharmacodynamic relationship between compound exposure, MK2 phosphorylation, and in vivo antitumor activity was observed. The fact that tumor growth inhibition by LY2228820 was observed in some, but not all, xenograft models tested supports the concept that p38a MAPK activity is cell and/or context dependent. Responsive xenografts are derived from several different histologies, have a variety of commonly considered mutations such as p53, KRAS, PTEN, PIK3CA, CDKN2A, and APC, and have cytokine profiles that range from little to no cytokine secretion (e.g., A2780) to high expressors of cytokines such as IL-6, CXCL8, and VEGF (e.g., U-87MG and 786-O). Yet both responsive and unresponsive subcutaneous xenograft tumors demonstrate p38 MAPK inhibition with LY2228820 treatment, as evidenced by reduced MK2 and HSP27 phosphorylation (data not shown).
Further support for the cell/context-dependent influence of p38 MAPK on cancer development and tumor growth is the observation that unresponsive tumors in the subcutaneous environment are responsive in the orthotopic environment. These findings are most readily understood if the p38 MAPK mechanism of action is primarily derived through tumor interaction with the TME. Recent data describing a role for p38 MAPK in angiogenesis support this tumor-TME interaction. Using both an in vitro measure of cord formation as well as an in vivo vascular development model, Tate and colleagues demonstrate that p38 MAPK inhibition by LY2228820 reduces angiogenesis both at the level of the stroma and at the level of the tumor cell itself (6) . The effects of LY2228820 on VEGF, cytokine levels, and angiogenesis in vitro were phenocopied by p38a MAPK shRNA, but not p38b MAPK shRNA, confirming the p38a MAPK dependency (6) . Similarly in this study, LY2228820-induced tumor growth delay in U-87MG tumor xenografts in vivo was phenocopied by p38a MAPK knockdown (Supplementary Fig. S2 ). In addition to the preclinical data, there is compelling clinical evidence suggesting p38 MAPK activity contributes to, or drives, several cancers by modulating the release of soluble, tumor supportive factors. Among its many activities, p38a MAPK stabilizes the message of various cytokines including TNF-a and CXCL8 and is required for IL-1 induction of IL-6 (2). Higher serum and alveolar lavage IL-6 and CXCL8 levels are associated with survival of patient with shorter lung cancer (40) . In addition, p38a MAPK is highly activated in NSCLC relative to normal lung tissue (41) . CXCL8 is also higher in the serum and cystic fluid from patients with ovarian cancer as compared with healthy patients or those with benign cysts (14) and increased CXCL8 expression correlated with more advanced stages of disease. In breast cancer, high levels of activated p38 MAPK have been correlated with invasive disease, tamoxifen resistance, and poor survival (42) (43) (44) (45) . Given these clinical observations, and the cumulative in vitro and in vivo preclinical data, it is possible that therapeutic inhibition of p38 MAPK could be effective clinically in reducing tumor growth, invasion, and metastasis.
In summary, LY2228820 is a potent and selective inhibitor of p38 MAPK with antitumor activity. Further studies are ongoing to determine the potential of this compound in other tumor types and in combination with standardof-care agents to determine, for example, whether p38 MAPK may be involved in drug resistance to traditional cytotoxic therapy (44, 45, 46) . Although there are a multitude of data linking p38 MAPK to tumor growth and metastasis via microenvironment interactions, it is still unclear how these effects manifest themselves across tumor types. The differences observed in response to LY228820 in vivo suggest there is likely more than one mechanism by which p38 MAPK drives tumor growth. The preclinical activity profile, drug-like properties, and pharmacodynamic effect on p-MK2, provide a compelling rationale to explore the clinical utility of this molecule in human cancer (47 
